Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study
The combination of chemotherapy with PD-1 inhibitors and lenvatinib demonstrates considerable efficacy and tolerability as a treatment strategy for patients with advanced ICC.
Authors
- Chengjun Sui (ORCID: https://orcid.org/0000-0002-3361-9788)
- Zhitao Dong
- Junwu Guo
- Binghua Dai (ORCID: https://orcid.org/0000-0003-3139-5749)
- Kecai Duan
- Geng Li (ORCID: https://orcid.org/0000-0002-7342-4539)
- Jiamei Yang
- Jiongjiong Lu
- Kui Wang (ORCID: https://orcid.org/0009-0000-7896-5046)
Institutions
- Second Military Medical University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.3389/fimmu.2024.1463574
- Citations
- 5
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Natural Science Foundation of Shanghai
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China